ATE216591T1 - Kombinationstherapie enthaltend ribavirin und interferon alpha bei patienten mit chronischer hepatitis c infektion, die nicht antiviral vorbehandelt sind - Google Patents

Kombinationstherapie enthaltend ribavirin und interferon alpha bei patienten mit chronischer hepatitis c infektion, die nicht antiviral vorbehandelt sind

Info

Publication number
ATE216591T1
ATE216591T1 AT99303729T AT99303729T ATE216591T1 AT E216591 T1 ATE216591 T1 AT E216591T1 AT 99303729 T AT99303729 T AT 99303729T AT 99303729 T AT99303729 T AT 99303729T AT E216591 T1 ATE216591 T1 AT E216591T1
Authority
AT
Austria
Prior art keywords
antivirals
infection
patients
combination therapy
interferon alpha
Prior art date
Application number
AT99303729T
Other languages
English (en)
Inventor
Janice K Albrecht
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22151354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE216591(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE216591T1 publication Critical patent/ATE216591T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT99303729T 1998-05-15 1999-05-13 Kombinationstherapie enthaltend ribavirin und interferon alpha bei patienten mit chronischer hepatitis c infektion, die nicht antiviral vorbehandelt sind ATE216591T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7956698A 1998-05-15 1998-05-15

Publications (1)

Publication Number Publication Date
ATE216591T1 true ATE216591T1 (de) 2002-05-15

Family

ID=22151354

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99303729T ATE216591T1 (de) 1998-05-15 1999-05-13 Kombinationstherapie enthaltend ribavirin und interferon alpha bei patienten mit chronischer hepatitis c infektion, die nicht antiviral vorbehandelt sind

Country Status (23)

Country Link
EP (3) EP0956861B1 (de)
JP (2) JP5281726B2 (de)
KR (1) KR100694345B1 (de)
CN (1) CN1230198C (de)
AR (1) AR019551A1 (de)
AT (1) ATE216591T1 (de)
AU (2) AU766597B2 (de)
BR (1) BR9910505A (de)
CA (1) CA2331823A1 (de)
CZ (1) CZ300540B6 (de)
DE (1) DE69901321T2 (de)
DK (1) DK0956861T3 (de)
ES (1) ES2172288T3 (de)
HK (1) HK1021131A1 (de)
HU (1) HU230432B1 (de)
IL (3) IL139220A0 (de)
MY (1) MY129244A (de)
NO (1) NO330715B1 (de)
NZ (1) NZ507621A (de)
PT (1) PT956861E (de)
SK (1) SK288038B6 (de)
TW (1) TWI277424B (de)
WO (1) WO1999059621A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2157000A (en) * 1998-12-18 2000-07-12 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
EP1244356A4 (de) * 1999-12-23 2003-03-19 Icn Pharmaceuticals Zusammensetzungen und verfahren zur herstellung von l-nucleosiden, l-nucleotiden und ihren analoga
JP4536194B2 (ja) * 2000-02-17 2010-09-01 大日本住友製薬株式会社 安定な注射用製剤
AU2001266557A1 (en) 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
AU2001272923A1 (en) 2000-05-26 2001-12-11 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
AU2002213343A1 (en) * 2000-10-18 2002-04-29 Schering Corporation Ribavirin-pegylated interferon alfa HCV combination therapy
US20030143197A1 (en) * 2001-11-09 2003-07-31 Moran S. Mark Method for treating diseases with omega interferon
WO2003060071A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7662798B2 (en) 2002-06-28 2010-02-16 Idenix Pharmaceuticals, Inc. 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN103319554A (zh) 2002-06-28 2013-09-25 埃迪尼克斯医药公司 用于治疗黄病毒感染的修饰的2’和3’-核苷前药
JP2006519753A (ja) 2002-11-15 2006-08-31 イデニクス（ケイマン）リミテツド ２’−分枝ヌクレオシドおよびフラビウイルス科ウイルス突然変異
US20050049204A1 (en) * 2003-03-28 2005-03-03 Otto Michael J. Compounds for the treatment of flaviviridae infections
CA2520148A1 (en) * 2003-04-01 2004-12-23 Intermune, Inc. Compositions and methods for treating coronavirus infection and sars
US20070026014A1 (en) * 2003-04-17 2007-02-01 Ares Trading S.A. Interferon beta in severe acute respiratory syndrome (sars)
SI2604620T1 (sl) 2003-05-30 2016-10-28 Gilead Pharmasset LLC c/o Gilead Sciences, Inc. Modificirani fluorirani nukleozidni analogi
US7482149B2 (en) * 2003-06-09 2009-01-27 Genome Institute Of Singapore Inhibition of SARS coronavirus infection with clinically approved antiviral drugs
CA2535451A1 (en) * 2003-08-13 2005-02-24 Howard J. Smith & Associates Pty Ltd. Method of treating viral infections
AR045870A1 (es) * 2003-10-11 2005-11-16 Vertex Pharma Terapia de combinacion para la infeccion de virus de hepatitis c
PT3109244T (pt) 2004-09-14 2019-06-04 Gilead Pharmasset Llc ¿preparação de ribofuranosil pirimidinas e purinas 2¿-fluoro-2¿-alquil substituídas ou outras opcionalmente substituídas e os seus derivados
TW201424733A (zh) * 2004-10-29 2014-07-01 Vertex Pharma 劑量型式
AP2907A (en) 2006-01-09 2014-05-31 Romark Lab Lc Viral hepatitis treatment
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
EP2175865A4 (de) 2007-07-25 2012-01-11 Biolex Therapeutics Inc Interferon-arzneiprodukte mit kontrollierter freisetzung und behandlung von hcv-infektionen damit
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
WO2010075517A2 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside analogs
EA019295B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Соединения пуриновых нуклеозидов и способ их получения
MX2011006891A (es) 2008-12-23 2011-10-06 Pharmasset Inc Fosforamidatos de nucleosidos.
US8716012B2 (en) 2009-05-08 2014-05-06 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
HUE034239T2 (en) 2010-03-31 2018-02-28 Gilead Pharmasset Llc Method for Crystallization of (S) -isopropyl 2 - (((S) (perfluorophenoxy) (phenoxy) phosphoryl) amino) propanoate \ t
WO2012045704A1 (en) * 2010-10-05 2012-04-12 Novartis Ag New treatments of hepatitis c virus infection
EP2646453A1 (de) 2010-11-30 2013-10-09 Gilead Pharmasset LLC Verbindungen
KR20190060879A (ko) * 2011-03-02 2019-06-03 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
DE202012013074U1 (de) 2011-09-16 2014-10-29 Gilead Pharmasset Lcc Zusammensetzungen zur Behandlung von HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
SG10201706949VA (en) 2013-01-31 2017-09-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
EP4005560A1 (de) 2013-08-27 2022-06-01 Gilead Pharmasset LLC Kombinationsformulierung von zwei antiviralen verbindungen

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4492537A (en) 1982-12-10 1985-01-08 Awerkamp John B Fluid-operated oil or water well pump
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
WO1995013090A1 (en) 1993-11-10 1995-05-18 Enzon, Inc. Improved interferon polymer conjugates
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
CA2329474C (en) * 1995-11-02 2002-02-26 Schering Corporation Continuous low-dose cytokine infusion therapy
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
CA2298543A1 (en) 1997-08-13 1999-02-25 James Barry Loading and release of water-insoluble drugs
ATE206618T1 (de) * 1997-09-21 2001-10-15 Schering Corp Kombinationstherapie zur entfernung von nachweisbarer hcv-rns in patienten mit chronischer hepatitis c-infektion

Also Published As

Publication number Publication date
NZ507621A (en) 2002-11-26
AU2005220271A1 (en) 2005-11-03
DE69901321D1 (de) 2002-05-29
JP5281726B2 (ja) 2013-09-04
DE69901321T2 (de) 2002-12-12
MY129244A (en) 2007-03-30
TWI277424B (en) 2007-04-01
AU3860099A (en) 1999-12-06
BR9910505A (pt) 2001-01-02
IL207259A (en) 2016-08-31
CN1309568A (zh) 2001-08-22
AU2005220271B2 (en) 2005-11-03
KR100694345B1 (ko) 2007-03-12
CZ300540B6 (cs) 2009-06-10
DK0956861T3 (da) 2002-07-01
EP0956861A1 (de) 1999-11-17
EP0956861B1 (de) 2002-04-24
NO330715B1 (no) 2011-06-20
HU230432B1 (hu) 2016-06-28
HK1021131A1 (en) 2000-06-02
EP1213029A1 (de) 2002-06-12
SK17102000A3 (sk) 2001-05-10
AU2005220271B9 (en) 2010-12-09
WO1999059621A1 (en) 1999-11-25
AU766597B2 (en) 2003-10-16
CZ20004177A3 (cs) 2001-04-11
HUP0103423A3 (en) 2003-11-28
HUP0103423A2 (hu) 2002-01-28
IL139220A (en) 2013-02-28
CA2331823A1 (en) 1999-11-25
JP2002515453A (ja) 2002-05-28
ES2172288T3 (es) 2002-09-16
PT956861E (pt) 2002-08-30
NO20005755L (no) 2001-01-12
EP2305287A1 (de) 2011-04-06
CN1230198C (zh) 2005-12-07
NO20005755D0 (no) 2000-11-14
IL139220A0 (en) 2001-11-25
SK288038B6 (en) 2013-01-02
AU2005220271B8 (en) 2010-11-18
AR019551A1 (es) 2002-02-27
JP2011173898A (ja) 2011-09-08
IL207259A0 (en) 2010-12-30
KR20010043624A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
ATE216591T1 (de) Kombinationstherapie enthaltend ribavirin und interferon alpha bei patienten mit chronischer hepatitis c infektion, die nicht antiviral vorbehandelt sind
HUP9802324A3 (en) Use of ribavirin and interferon alpha for the treatment of hepatitis c
DE69801970T2 (de) Kombinationstherapie zur Entfernung von nachweisbarer HCV-RNS in Patienten mit chronischer Hepatitis C-Infektion
DK1087778T3 (da) Anvendelse af PEG-IFN-alfa og Ribavirin til behandling af kronisk hepatitis C
NO20031742L (no) HCV-kombinasjonsterapi med ribavirin og pegylert interferon alfa
PT712862E (pt) Acilacao selectiva de grupos epsilon-amino em ensulina
NO20015059D0 (no) HCV-kombinasjonsterapi, inneholdende ribavirin i assosiasjon med antioksydanter
PL311031A1 (en) Use of concentrates comprising vwf in complex therapy in case of treatment by using anticoagulants and fibrinolitic drugs
IT1299969B1 (it) Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della retinopatia diabetica.
ATA22989A (de) Behandlungsliege, insbesondere massageliege
ATE348628T1 (de) Behandlung von hepatitis c mit thymosin, interferon und ribavirin
SI1311279T1 (sl) Zdravljenje hepatitisa c s timozinom, interferonom in ribavirinom
SI1077068T1 (en) Utilization of interferon alpha 5 in the treatment of viral hepatopathies
BR6900836U (pt) Disposicao introduzida em conjunto de mesa e cadeiras
DE29508076U1 (de) Säge und Frästisch mit kugelgelagertem Spannschlitten
BR9202811A (pt) Aperfeicoamento aplicado em jogo recreativo de mesa
DE9408782U1 (de) Nachttisch mit verstellbarer Reling
IT8648366A0 (it) Diossepano,suo procedimentodi sintesi e sue applicazioni in terapia
BR7000950U (pt) Utensilio aplicavel em ginastica terapeutica e estetica facial
BR6800609U (pt) Conjunto de cadeira,mesa e lousa
BR7401305U (pt) Aperfeiçoamento em cateter de oxigenação
BR8801541A (pt) Aperfeicoamento em panelas,dispositivo e revestimento descartavel
BR8806886A (pt) Aperfeicoamento em jogo de futebol de mesa
BR6901294U (pt) Disposicao introduzida em jogo de mesa
SE9501896D0 (sv) Personlyft i badkar